{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113883.3.3157.4020",
  "meta": {
    "versionId": "14",
    "lastUpdated": "2024-09-06T09:14:11.000-04:00",
    "profile": [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate": "2020-08-21"
    }
  ],
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4020",
  "identifier": [
    {
      "system": "urn:ietf:rfc:3986",
      "value": "urn:oid:2.16.840.1.113883.3.3157.4020"
    }
  ],
  "version": "20200821",
  "name": "FibrinolyticTherapy",
  "title": "Fibrinolytic Therapy",
  "status": "retired",
  "experimental": false,
  "date": "2022-03-08T01:02:00-05:00",
  "publisher": "Acumen OP Steward",
  "expansion": {
    "identifier": "urn:uuid:9bc2296b-ac19-4bc4-8d3d-d8e10e191f3f",
    "timestamp": "2024-10-02T12:27:05-04:00",
    "total": 22,
    "offset": 0,
    "parameter": [
      {
        "name": "count",
        "valueInteger": 1000
      },
      {
        "name": "offset",
        "valueInteger": 0
      }
    ],
    "contains": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "09032024",
        "code": "1804799",
        "display": "alteplase 100 MG Injection"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "09032024",
        "code": "1804804",
        "display": "alteplase 50 MG Injection"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "21464-3",
        "display": "Plasminogen activator urokinase type [Presence] in Tissue"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "09032024",
        "code": "313212",
        "display": "tenecteplase 50 MG Injection"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "43636-0",
        "display": "Plasminogen activator tissue type [Presence] in Platelet poor plasma by Chromogenic method"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "5971-7",
        "display": "Plasminogen activator tissue type Ag [Mass/volume] in Platelet poor plasma by Immunoassay"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "5972-5",
        "display": "Plasminogen activator tissue type Ag [Mass/volume] in Platelet poor plasma by Immunoassay --20 minutes post venistasis"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "5973-3",
        "display": "Plasminogen activator tissue type Ag [Mass/volume] in Platelet poor plasma by Immunoassay --10 minutes post venistasis"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "5981-6",
        "display": "Plasminogen activator tissue type-Plasminogen activator inhibitor 1 complex [Mass/volume] in Platelet poor plasma by Immunoassay"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "5982-4",
        "display": "Plasminogen activator tissue type-Plasminogen activator inhibitor 1 complex [Mass/volume] in Platelet poor plasma by Immunoassay --20 minutes post venistasis"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "5983-2",
        "display": "Plasminogen activator tissue type-Plasminogen activator inhibitor 1 complex [Mass/volume] in Platelet poor plasma by Immunoassay --10 minutes post venistasis"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "5986-5",
        "display": "Plasminogen activator tissue type [Units/volume] in Platelet poor plasma by Chromogenic method"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "5987-3",
        "display": "Plasminogen activator tissue type [Mass/volume] in Platelet poor plasma by Chromogenic method"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "5988-1",
        "display": "Plasminogen activator tissue type [Mass/volume] in Platelet poor plasma by Chromogenic method --10 minutes post venistasis"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "5989-9",
        "display": "Plasminogen activator tissue type [Units/volume] in Platelet poor plasma by Chromogenic method --10 minutes post venistasis"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "5990-7",
        "display": "Plasminogen activator tissue type [Units/volume] in Platelet poor plasma by Chromogenic method --20 minutes post venistasis"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "09032024",
        "code": "763138",
        "display": "reteplase 10 UNT Injection"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "88659-8",
        "display": "Timing of thrombolytic administration in relation to cardiac arrest"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "LP16885-3",
        "display": "Plasminogen activator tissue type Ag"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "LP16889-5",
        "display": "Plasminogen activator tissue type-Plasminogen activator inhibitor 1 complex"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "LP16891-1",
        "display": "Plasminogen activator tissue type"
      },
      {
        "system": "http://loinc.org",
        "version": "2.78",
        "code": "LP265990-4",
        "display": "Timing of thrombolytic administration in relation to cardiac arrest"
      }
    ]
  }
}